CN107080769A - 一种治疗各种慢性疾病的天然药物及医用配方食品 - Google Patents
一种治疗各种慢性疾病的天然药物及医用配方食品 Download PDFInfo
- Publication number
- CN107080769A CN107080769A CN201710348486.1A CN201710348486A CN107080769A CN 107080769 A CN107080769 A CN 107080769A CN 201710348486 A CN201710348486 A CN 201710348486A CN 107080769 A CN107080769 A CN 107080769A
- Authority
- CN
- China
- Prior art keywords
- parts
- chronic diseases
- natural drug
- formula food
- various chronic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 22
- 235000013305 food Nutrition 0.000 title claims abstract description 20
- 208000017667 Chronic Disease Diseases 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims abstract description 18
- 230000000694 effects Effects 0.000 claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 10
- 210000004369 blood Anatomy 0.000 claims abstract description 10
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims abstract description 9
- JYYFMIOPGOFNPK-UHFFFAOYSA-N ethyl linolenate Natural products CCOC(=O)CCCCCCCC=CCC=CCC=CCC JYYFMIOPGOFNPK-UHFFFAOYSA-N 0.000 claims abstract description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 8
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 7
- 235000004347 Perilla Nutrition 0.000 claims abstract description 7
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 7
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 7
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 7
- 239000001168 astaxanthin Substances 0.000 claims abstract description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 7
- 229940114079 arachidonic acid Drugs 0.000 claims abstract 2
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract 2
- 208000005189 Embolism Diseases 0.000 claims description 7
- 241000229722 Perilla <angiosperm> Species 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 9
- 210000001367 artery Anatomy 0.000 abstract description 7
- 208000034189 Sclerosis Diseases 0.000 abstract description 5
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 230000003073 embolic effect Effects 0.000 abstract description 3
- 230000010102 embolization Effects 0.000 abstract description 2
- 244000124853 Perilla frutescens Species 0.000 abstract 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 3
- 244000105624 Arachis hypogaea Species 0.000 description 3
- 235000010777 Arachis hypogaea Nutrition 0.000 description 3
- 235000018262 Arachis monticola Nutrition 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001336 alkenes Chemical class 0.000 description 3
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
- 235000020232 peanut Nutrition 0.000 description 3
- 241000143060 Americamysis bahia Species 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Emergency Medicine (AREA)
- Alternative & Traditional Medicine (AREA)
Abstract
本发明公开了一种治疗各种慢性疾病的天然药物及医用配方食品,包括以下成分的含量为:虾青素:0.5‑2.5份,DHA:10‑21份,EPA:5‑10份,α亚麻酸乙酯:11‑29份,辅酶Q10:0.2‑1.3份,花生四烯酸:1.0—5份,紫苏油:35‑65份。本发明是治疗因动脉硬化和血栓塞引起的各种慢性疾病的天然药物及医用配方食品,根据中医药配和理论,它的作用能降脂,治疗动脉硬化引起的心脑血管疾病和糖尿病综合证、高血压及各种栓塞疾病。
Description
技术领域
本发明涉及治疗血栓塞疾病技术领域,尤其涉及一种治疗各种慢性疾病的天然药物及医用配方食品。
背景技术
对于因栓塞及动脉硬化引起的,各种疾病已经成为人们的头号杀手,当前治疗方法多都采用支架,西药或注射,但是这都只能暂时缓解,只能治标不治本,所以这类疾病人群比例只增不减,这是因为没有找到病的根源,救治不了根本。
发明内容
本发明的目的是为了解决现有技术中存在的缺点,而提出的一种治疗各种慢性疾病的天然药物及医用配方食品。
一种治疗各种慢性疾病的天然药物及医用配方食品,包括以下成分的含量为:虾青素:0.5-2.5份,DHA:10-21份,EPA:5-10份,α亚麻酸乙酯:11-29份,辅酶Q10:0.2-1.3份,花生四烯酸:1-5份,紫苏油:35-65份。
一种治疗各种慢性疾病的天然药物及医用配方食品,包括以下成分的含量为:虾青素:1份,DHA:10份,EPA:7份,α亚麻酸乙酯:20份,辅酶Q10:1.2份,花生四烯酸:3份,紫苏油:57.8份。
本发明还提供了一种治疗各种慢性疾病的天然药物及医用配方食品食用方法,其特征在于,具体如下;
a.预防动脉硬化每天服用5g,可连服用2-5个月;
b.降血脂,血粘稠每次服用5g,每天2次,7天见效、1-2月治愈率达98%;
c. 糖尿病综合症每天服用15g,每天2次,1个月见效,3-5个月治愈率达65%;
d. 心脏病每天服用10-15g,每天2次,1-3个治愈率达90%;
e. 各种栓塞病症,每天服用15g,每天2次,2-3个月治愈率达85%。
本发明解决的技术方案为采用、虾青素,DHA、EPA、α亚麻酸乙酯、辅酶Q10、花生四烯酸、按不同量的的配比后混合而制成。根据中医药配和理论,它的作用能降脂,治疗动脉硬化引起的心脑血管疾病和糖尿病综合证、高血压及各种栓塞疾病,可以从根本上预防和治疗因动脉硬化和血栓栓塞引起的各种慢性疾病的天然药物和医用配方食品食品。
具体实施方式
下面结合具体实施例对本发明作进一步解说。
实施例一
一种治疗各种慢性疾病的天然药物及医用配方食品,包括以下成分的含量为:虾青素:0.5-2.5份,DHA:10-21份,EPA:5-10份,α亚麻酸乙酯:11-29份,辅酶Q10:0.2-1.3份,花生四烯酸:1-5份,紫苏油:35-65份。
本发明还提供了一种治疗各种慢性疾病的天然药物及医用配方食品食用方法,其特征在于,具体如下;
a.预防动脉硬化每天服用5g,可连服用2-5个月;
b.降血脂,血粘稠每次服用5g,每天2次,7天见效、1-2月治愈率达98%;
c. 糖尿病综合症每天服用15g,每天2次,1个月见效,3-5个月治愈率达65%;
d. 心脏病每天服用10-15g,每天2次,1-3个治愈率达90%;
e. 各种栓塞病症,每天服用15g,每天2次,2-3个月治愈率达85%。
实施例二
一种治疗各种慢性疾病的天然药物及医用配方食品,包括以下成分的含量为:虾青素:1份,DHA:10份,EPA:7份,α亚麻酸乙酯:20份,辅酶Q10:1.2份,花生四烯酸:3份,紫苏油:57.8份。
本发明还提供了一种治疗各种慢性疾病的天然药物及医用配方食品食用方法,其特征在于,具体如下;
a.预防动脉硬化每天服用5g,可连服用2-5个月;
b.降血脂,血粘稠每次服用5g,每天2次,7天见效、1-2月治愈率达98%;
c. 糖尿病综合症每天服用15g,每天2次,1个月见效,3-5个月治愈率达65%;
d. 心脏病每天服用10-15g,每天2次,1-3个治愈率达90%;
e. 各种栓塞病症,每天服用15g,每天2次,2-3个月治愈率达85%。
本发明解决的技术方案为采用、虾青素,DHA、EPA、α亚麻酸乙酯、辅酶Q10、花生四烯酸、按不同量的的配比后混合而制成。根据中医药配和理论,它的作用能降脂,治疗动脉硬化引起的心脑血管疾病和糖尿病综合证、高血压及各种栓塞疾病,可以从根本上预防和治疗因动脉硬化和血栓栓塞引起的各种慢性疾病的天然药物和医用配方食品食品。
以上所述,仅为本发明较佳的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,根据本发明的技术方案及其发明构思加以等同替换或改变,都应涵盖在本发明的保护范围之内。
Claims (3)
1.一种治疗各种慢性疾病的天然药物及医用配方食品,其特征在于,包括以下成分的含量为:虾青素:0.5-2.5份,DHA:10-21份,EPA:5-10份,α亚麻酸乙酯:11-29份,辅酶Q10:0.2-1.3份,花生四烯酸:1-5份,紫苏油:35-65份。
2.一种治疗各种慢性疾病的天然药物及医用配方食品,其特征在于,包括以下成分的含量为:虾青素:1份,DHA:10份,EPA:7份,α亚麻酸乙酯:20份,辅酶Q10:1.2份,花生四烯酸:3份,紫苏油:57.8份。
3.本发明还提供了一种治疗各种慢性疾病的天然药物及医用配方食品食用方法,其特征在于,具体如下;
a.预防动脉硬化每天服用5g,可连服用2-5个月;
b.降血脂,血粘稠每次服用5g,每天2次,7天见效、1-2月治愈率达98%;
c. 糖尿病综合症每天服用15g,每天2次,1个月见效,3-5个月治愈率达65%;
d. 心脏病每天服用10-15g,每天2次,1-3个治愈率达90%;
e. 各种栓塞病症,每天服用15g,每天2次,2-3个月治愈率达85%。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710348486.1A CN107080769A (zh) | 2017-05-17 | 2017-05-17 | 一种治疗各种慢性疾病的天然药物及医用配方食品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710348486.1A CN107080769A (zh) | 2017-05-17 | 2017-05-17 | 一种治疗各种慢性疾病的天然药物及医用配方食品 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107080769A true CN107080769A (zh) | 2017-08-22 |
Family
ID=59608944
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710348486.1A Pending CN107080769A (zh) | 2017-05-17 | 2017-05-17 | 一种治疗各种慢性疾病的天然药物及医用配方食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107080769A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112691092A (zh) * | 2021-02-05 | 2021-04-23 | 云南维他源生物科技有限公司 | 一种治疗缺血性心脏病的药物组合物及其制剂与应用 |
US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2124608A2 (en) * | 2007-01-19 | 2009-12-02 | The Iams Company | Composition and method of stabilized sensitive ingredient |
CN103501623A (zh) * | 2011-02-11 | 2014-01-08 | 大德Frd有限公司 | 用于生产磷虾油的方法以及由所述方法生产的磷虾油 |
CN104082751A (zh) * | 2014-06-29 | 2014-10-08 | 宁波市成大机械研究所 | 一种含有虾青素的深海鱼油软胶囊 |
CN104082741A (zh) * | 2014-06-29 | 2014-10-08 | 宁波市成大机械研究所 | 一种含有虾青素的海狗油软胶囊 |
-
2017
- 2017-05-17 CN CN201710348486.1A patent/CN107080769A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2124608A2 (en) * | 2007-01-19 | 2009-12-02 | The Iams Company | Composition and method of stabilized sensitive ingredient |
CN103501623A (zh) * | 2011-02-11 | 2014-01-08 | 大德Frd有限公司 | 用于生产磷虾油的方法以及由所述方法生产的磷虾油 |
CN104082751A (zh) * | 2014-06-29 | 2014-10-08 | 宁波市成大机械研究所 | 一种含有虾青素的深海鱼油软胶囊 |
CN104082741A (zh) * | 2014-06-29 | 2014-10-08 | 宁波市成大机械研究所 | 一种含有虾青素的海狗油软胶囊 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11696593B2 (en) | 2018-08-24 | 2023-07-11 | Bioscience Formulators, LLC | Astaxanthin nutritional compositions and uses |
CN112691092A (zh) * | 2021-02-05 | 2021-04-23 | 云南维他源生物科技有限公司 | 一种治疗缺血性心脏病的药物组合物及其制剂与应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20180064362A (ko) | 셀룰라이트 개선성분 및 항산화 유효성분, 부종감소 및 통증완화 성분을 함유한 다이어트 주사용 조성물 | |
CA2648126A1 (en) | Treatments using citrulline | |
RU2017140424A (ru) | Рацион, имитирующий воздержание от пищи и улучшающий состояние организма, для лечения гипертонии и расстройств липидного обмена | |
Grygiel-Górniak et al. | Fatigue and interleukin-6–a multi-faceted relationship | |
CN107080769A (zh) | 一种治疗各种慢性疾病的天然药物及医用配方食品 | |
CN101579124A (zh) | 怀山药营养保健面粉 | |
CN108079122A (zh) | 一种治疗脂肪肝的药物 | |
Jarouliya et al. | Nutraceutical components in the treatment of psoriasis and psoriatic arthritis | |
US20200276436A1 (en) | Method for treating sepsis and septic shock | |
CN101301358B (zh) | 一种治疗溃疡性睑缘炎的外洗药物 | |
CN105582126A (zh) | 一种治疗口腔溃疡的药物 | |
Adad | Fellowship submission: Manifestations and possible treatment modalities for post-acute sequelae of covid-19 (" long covid") and vaccine-injured patients | |
Adad | MANIFESTATIONS AND POSSIBLE TREATMENT MODALITIES FOR POST-ACUTE SEQUELAE OF COVID-19 (" LONG COVID") AND VACCINE-INJURED PATIENTS. | |
Jarouliya et al. | 18 Nutraceutical Components | |
CN105395574A (zh) | 一种药食两用防治心脑血管病复方角鲨烯鱼油软胶囊 | |
JPH0466528A (ja) | 炎症性腸疾患用油脂組成物 | |
US20150190451A1 (en) | Herbal Composition and a Method for the Treatment of Hyperlipidemia Caused by Excessive Consumption of Lamb | |
CN105726718A (zh) | 治疗跌损腰痛的中药 | |
CN107789551A (zh) | 一种治疗湿疹的中药组合物 | |
CN104432067A (zh) | 一种缓解女性更年期综合症的保健食品 | |
RU2426452C2 (ru) | Композиция для приготовления биологически активной добавки к пище | |
Tolstikova et al. | EFFICIENCY OF ALPHA-LIPOIC ACID IN METABOLIC SYNDROME TREATMENT IN CHILDREN | |
KR20180093599A (ko) | 애엽 추출물을 포함하는 특수 약침 | |
Campbell II | Plant-based Diets for Cardiovascular Disease: A Brief Review | |
CN107714912A (zh) | 一种治疗月经先后无定期的中药组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170822 |